Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

Synergistic PD‐1/LAG‐3 Inhibition: Mechanistic Insights and Implications for Enhanced Tumor Immunotherapy

Saved in:

Bibliographic Details
Main Authors:	Jianqiao Shentu, Hening Xu, Shiwei Duan
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	MedComm
Online Access:	https://doi.org/10.1002/mco2.70216
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ammonia-induced lysosomal and mitochondrial damage: a novel perspective on T cell-based cancer immunotherapy
by: Jianqiao Shentu, et al.
Published: (2025-04-01)

DMB-induced GSDMD-mediated pyroptosis: a novel therapeutic strategy for enhancing anti-tumor immunity
by: Jianqiao Shentu, et al.
Published: (2024-11-01)

Mechanistic insights into synergistic effects using coupled PK-PD modeling
by: Jinzhou Sun, et al.
Published: (2025-05-01)

Co-occurrence of AIDS and acute promyelocytic leukemia: a case report and review of the literature
by: Cheng Ai, et al.
Published: (2025-07-01)

Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies
by: Yizhou Zhang, et al.
Published: (2024-12-01)

Combination immunotherapy targeting LAG-3, PD-1 and STING suppresses hepatocellular carcinoma as monitored by LAG-3 targeted PET imaging
by: Zhen Quan, et al.
Published: (2025-08-01)

Lag-3 expression and clinical outcomes in metastatic melanoma patients treated with combination anti-lag-3 + anti-PD-1-based immunotherapies
by: Tuba N. Gide, et al.
Published: (2023-12-01)

Escherichia coli combination with PD-1 blockade synergistically enhances immunotherapy in glioblastoma multiforme by regulating the immune cells
by: Guochen Li, et al.
Published: (2025-02-01)

Parvoviruses NS1 oncolytic attributes: mechanistic insights and synergistic anti-tumor therapeutic strategies
by: Abdul Haseeb, et al.
Published: (2025-08-01)

Enhanced cancer immunotherapy via synergistic action of NO-Donor nanoparticles (NanoARG) and PD-1 antibody
by: Ting Mei, et al.
Published: (2025-12-01)

Noninvasive Immunotyping and Immunotherapy Monitoring of Lung Cancers via Nuclear Imaging of LAG‐3 and PD‐L1
by: Lishu Zhao, et al.
Published: (2025-01-01)

Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy
by: Yi-Yu Wang, et al.
Published: (2025-04-01)

Targeting pyroptosis for cancer immunotherapy: mechanistic insights and clinical perspectives
by: Chen Huang, et al.
Published: (2025-05-01)

Tumor microenvironment-responsive nanoplatforms for enhanced cancer immunotherapy: Advances and synergistic strategies
by: Jie Wu, et al.
Published: (2025-12-01)

Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: the first-in-human phase Ia/Ib study
by: Chenyu Mao, et al.
Published: (2024-12-01)

Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
by: Sergio Ayala-Mar, et al.
Published: (2021-01-01)

Reversing VTN deficiency inhibits the progression of pancreatic cancer and enhances sensitivity to anti-PD1 immunotherapy
by: Siqi Zhao, et al.
Published: (2025-05-01)

Tumor Metastasis: Mechanistic Insights and Therapeutic Intervention
by: Lin Tang, et al.
Published: (2025-03-01)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
by: Alfred Zippelius, et al.
Published: (2022-11-01)

Synergistic catalysis by AlB doped Pd/AC for selective conversion of pulegone to thymol: Mechanistic elucidation and process intensification
by: Prashant Kumar, et al.
Published: (2025-08-01)

Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects
by: Zahid Rafiq, et al.
Published: (2025-01-01)

Microbiota-derived metabolites in tumorigenesis: mechanistic insights and therapeutic implications
by: Si-Fu Yang, et al.
Published: (2025-05-01)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
by: Li Liu, et al.
Published: (2022-12-01)

Mechanistic Insights into the Synergistic Effects of SGLT-2 Inhibitors and ACE Inhibitors/ARBs: Implications for Cardiovascular and Renal Protection in Type 2 Diabetes Mellitus and Beyond
by: Sulthan Al Rashid, et al.
Published: (2024-07-01)

Tecovirimat: A journey from discovery to mechanistic insights in poxvirus inhibition.
by: Xue Li, et al.
Published: (2025-05-01)

Inhibition of Tyrosinase and Melanogenesis by Carboxylic Acids: Mechanistic Insights and Safety Evaluation
by: Yu-Pei Chen, et al.
Published: (2025-04-01)

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
by: Xinchen Lu, et al.
Published: (2025-01-01)

Lichen Planus-Like Exanthema Induced by Anti-PD-1 and Anti-LAG-3 Combination Immunotherapy Could Potentially Predict the Treatment Response in Metastatic Melanoma
by: Marek Pasek, et al.
Published: (2025-01-01)

Mitochondrial Ribosomal Protein Family in Cancers: Mechanistic Insights and Therapeutic Implications
by: Qian Chen, et al.
Published: (2025-06-01)

TMEM16A in prostate cancer: mechanistic insights and therapeutic implications
by: Jia Wei He, et al.
Published: (2025-07-01)

Unveiling the Reactivity of Fluoropolymers with Sodium Metal: Mechanistic Insights and Battery Implications
by: Cheng-Tien Hsieh, et al.
Published: (2025-06-01)

Extracellular vesicles in cancer drug resistance: Mechanistic insights and therapeutic implications
by: Jing Zuo, et al.
Published: (2024-12-01)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
by: Yi Duan, et al.
Published: (2022-03-01)

Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer
by: Chengquan Shen, et al.
Published: (2025-07-01)

Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer
by: Songhua Cai, et al.
Published: (2025-06-01)

Effects of chemoradiotherapy on surface PD-L1 expression in esophageal cancer and its implications for immunotherapy
by: Lovis Hampe, et al.
Published: (2024-12-01)

Synergistic potential of CDH3 in targeting CRC metastasis and enhancing immunotherapy
by: Chen Fu, et al.
Published: (2025-03-01)

Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party
by: Chenyu Lu, et al.
Published: (2024-03-01)

Decoding the tumor microenvironment: insights into immunotherapy and beyond
by: Wenhao Xu, et al.
Published: (2025-08-01)

Synthesis and Cytotoxicity Evaluation of Denitroaristolochic Acids: Structural Insights and Mechanistic Implications in Nephrotoxicity
by: Jianfei Gao, et al.
Published: (2025-07-01)